Advertisement

Does Noncompliance in Lymph Node Dissection Affect Oncological Efficacy in Gastric Cancer Patients Undergoing Radical Gastrectomy?

  • Qi-Yue Chen
  • Qing Zhong
  • Zhi-Yu Liu
  • Jian-Wei Xie
  • Jia-Bin Wang
  • Jian-Xian Lin
  • Jun Lu
  • Long-Long Cao
  • Mi Lin
  • Ru-Hong Tu
  • Ze-Ning Huang
  • Ju-Li Lin
  • Ping LiEmail author
  • Chao-Hui ZhengEmail author
  • Chang-Ming HuangEmail author
Gastrointestinal Oncology

Abstract

Background

Few reports have examined the prognosis of or possible remedial treatments for patients with noncompliant D2 lymphadenectomy. We investigated the effect of noncompliance in lymph node (LN) dissection on long-term survival in gastric cancer (GC) patients after radical gastrectomy and explored intervention measures.

Methods

Clinicopathological data were retrospectively analyzed in 2401 patients who underwent radical gastrectomy for GC. Noncompliance was defined as patients with more than one empty LN station, as described in the protocol of the Japanese GC Association.

Results

The overall noncompliance rate was 49.1%. The 3-year overall survival (OS) rate was significantly better in compliant than noncompliant patients (74.0% vs. 60.1%, P < 0.001). Univariate and multivariate analyses revealed that noncompliance was an independent risk factor for OS. Logistic regression analysis demonstrated that extent of gastrectomy, primary tumor site, history of intraperitoneal surgery, body mass index, and open gastrectomy were independent preoperative predictive factors for noncompliance. Cox analysis demonstrated that age, pT, pN, and extent of gastrectomy independently affected OS in patients with noncompliant lymphadenectomy. However, OS was significantly better in the compliant than noncompliant group regardless of the recommendation for chemotherapy. Stratified analysis demonstrated that OS was significantly better in chemotherapy patients than in patients without chemotherapy and stage II patients (pT1N2/N3M0 and pT3N0M0) in whom chemotherapy was not recommended.

Conclusions

Noncompliance is an independent risk factor after radical gastrectomy for GC. Adjuvant chemotherapy improved the prognosis of patients with pT1N2/N3M0 and pT3N0M0 disease who underwent noncompliant D2 lymphadenectomy.

Notes

Acknowledgements

Sponsored by Scientific and Technological Innovation Joint Capital Projects of Fujian Province (2016Y9031), Construction Project of Fujian Province Minimally Invasive Medical Center (No. [2017]171), the second batch of special support funds for Fujian Province innovation and entrepreneurship talents (2016B013), general project of Miaopu Scientific Research Fund of Fujian Medical University (2015MP021), Youth Project of Fujian Provincial Health and Family Planning Commission (2016-1-41), and Nature Fund Health Joint Fund Project of Fujian Province (2015J01464).

Authors’ contribution

QYC, QZ, ZYL and JWX conceived of the study, analyzed the data, and drafted the manuscript; WBW, JXL, PL, CHZ, CMH, JL, LLC and ML helped revise the manuscript critically for important intellectual content; RHT, ZNH and JLL helped collect data and design the study. All authors read and approved the final manuscript.

Supplementary material

10434_2019_7217_MOESM1_ESM.tif (1.1 mb)
Supplementary Figure 1. Overall survival in patients with compliant lymphadenectomy and noncompliant lymphadenectomy (TIFF 1157 kb)
10434_2019_7217_MOESM2_ESM.doc (33 kb)
Supplementary material 2 (DOC 33 kb)
10434_2019_7217_MOESM3_ESM.doc (33 kb)
Supplementary material 3 (DOC 33 kb)
10434_2019_7217_MOESM4_ESM.doc (40 kb)
Supplementary material 4 (DOC 40 kb)
10434_2019_7217_MOESM5_ESM.doc (40 kb)
Supplementary material 5 (DOC 39 kb)
10434_2019_7217_MOESM6_ESM.doc (31 kb)
Supplementary material 6 (DOC 31 kb)
10434_2019_7217_MOESM7_ESM.doc (82 kb)
Supplementary material 7 (DOC 82 kb)
10434_2019_7217_MOESM8_ESM.doc (30 kb)
Supplementary material 8 (DOC 30 kb)

References

  1. 1.
    Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2015;61(2):69–90CrossRefGoogle Scholar
  2. 2.
    Torre LA, Bray F, Siegel RL, Ferlay J, Lortettieulent J, Jemal A. GLOBOCAN 2012: estimated cancer incidence mortality and prevalence worldwide in 2012. 2015.Google Scholar
  3. 3.
    Cuschieri A, Weeden S, Fielding J, et al. Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical co-operative group. Br J Cancer. 1999;79(10):1522–1530CrossRefGoogle Scholar
  4. 4.
    Schwarz RE, Smith DD. Clinical impact of lymphadenectomy extent in resectable gastric cancer of advanced stage. Ann Surg Oncol. 2007;14(2):317–328CrossRefGoogle Scholar
  5. 5.
    Seevaratnam R, Bocicariu A, Cardoso R, et al. How many lymph nodes should be assessed in patients with gastric cancer? A systematic review. Gastric Cancer. 2012;15(1):70–88.CrossRefGoogle Scholar
  6. 6.
    Bonenkamp JJ, Songun I, Hermans J, et al. Randomised comparison of morbidity after D1 and D2 dissection for gastric cancer in 996 Dutch patients. Lancet. 1995;345(8952):745.CrossRefGoogle Scholar
  7. 7.
    Siewert JR, Böttcher K, Stein HJ, Roder JD. Relevant prognostic factors in gastric cancer: ten-year results of the German Gastric Cancer Study. Ann Surg. 1998;228(4):449–461.CrossRefGoogle Scholar
  8. 8.
    Songun I, Putter H, Kranenbarg EM, Sasako M, Cj VDV. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–449.CrossRefGoogle Scholar
  9. 9.
    Bonenkamp JJ, Hermans J, Sasako M, et al. Extended lymph-node dissection for gastric cancer. N Engl J Med. 1999;340(12):908.CrossRefGoogle Scholar
  10. 10.
    De Steur WO, Hartgrink HH, Dikken JL, Putter H, Van de Velde CJ. Quality control of lymph node dissection in the Dutch Gastric Cancer Trial. Br J Surg. 2015;102(11):1388–1393.CrossRefGoogle Scholar
  11. 11.
    Association. JGC. Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101–112.CrossRefGoogle Scholar
  12. 12.
    Chen QY, Zheng CH, Li P, et al. Which method is more suitable for advanced gastric cancer with enlarged lymph nodes, laparoscopic radical gastrectomy or open gastrectomy? Gastric Cancer. 2018;28(suppl_3):1–11.Google Scholar
  13. 13.
    Association JGC. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14(2):113–123.CrossRefGoogle Scholar
  14. 14.
    Huang CM, Chen QY, Lin JX, et al. Laparoscopic suprapancreatic lymph node dissection for advanced gastric cancer using a left-sided approach. Ann Surg Oncol. 2015;22(7):2351.CrossRefGoogle Scholar
  15. 15.
    Huang CM, Chen QY, Lin JX, et al. Laparoscopic spleen-preserving no. 10 lymph node dissection for advanced proximal gastric cancer using a left approach. Ann Surg Oncol. 2014;21(6):2051.CrossRefGoogle Scholar
  16. 16.
    Chen QY, Huang CM, Lin JX, et al. Laparoscopic infrapyloric area lymph node dissection with no. 14v enlargement for advanced lower gastric cancer in middle colic vein approach. Ann Surg Oncol. 2016;23(3):951.CrossRefGoogle Scholar
  17. 17.
    Huang CM, Chen QY, Lin JX, Zheng CH, Li P, Xie JW. Huang’s three-step maneuver for laparoscopic spleen-preserving No. 10 lymph node dissection for advanced proximal gastric cancer. Chin J Cancer Res. 2014;26(2):208–210.Google Scholar
  18. 18.
    Lin JX, Huang CM, Zheng CH, et al. Evaluation of laparoscopic total gastrectomy for advanced gastric cancer: results of a comparison with laparoscopic distal gastrectomy. Surg Endosc. 2016;30(5):1988.CrossRefGoogle Scholar
  19. 19.
    Lu J, Wang W, Zheng CH, et al. Influence of total lymph node count on staging and survival after gastrectomy for gastric cancer: an analysis from a two-institution database in China. Ann Surg Oncol. 2017;24(2):1–8.CrossRefGoogle Scholar
  20. 20.
    Tu RH, Lin JX, Zheng CH, et al. Development of a nomogram for predicting the risk of anastomotic leakage after a gastrectomy for gastric cancer. Eur J Surg Oncol. 2016;43(2): 485–492.CrossRefGoogle Scholar
  21. 21.
    Grambsch PM, Therneau TM (1994) Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 81(3):515–526CrossRefGoogle Scholar
  22. 22.
    eong O, Park YK. Clinicopathological features and surgical treatment of gastric cancer in South Korea: the results of 2009 nationwide survey on surgically treated gastric cancer patients. J Gastric Cancer. 2011;11(2):69–77.CrossRefGoogle Scholar
  23. 23.
    Miyahara R, Niwa Y, Matsuura T, et al. Prevalence and prognosis of gastric cancer detected by screening in a large Japanese population: data from a single institute over 30 years. J Gastroenterol Hepatol. 2007;22(9):1435–1442.CrossRefGoogle Scholar
  24. 24.
    Park YK, Yoon HM, Kim YW, et al. Laparoscopy-assisted versus open D2 distal gastrectomy for advanced gastric cancer: results from a randomized phase II multicenter clinical trial (COACT 1001). Ann Surg. 2017;42(9):S98–S99.Google Scholar
  25. 25.
    Peeters KC, Hundahl SA, Kranenbarg EK, Hartgrink H, Cj VDV. Low Maruyama index surgery for gastric cancer: blinded reanalysis of the Dutch D1-D2 trial. World J Surg. 2005;29(12):1576–1584.CrossRefGoogle Scholar
  26. 26.
    Karpeh MS, Leon L, Klimstra D, Brennan MF. Lymph node staging in gastric cancer: is location more important than Number? An analysis of 1038 patients. Ann Surg. 2000;232(3):362–371.CrossRefGoogle Scholar
  27. 27.
    Liu X, Long Z, Cai H, Huang H, Shi Y, Wang Y. Analysis of lymph node metastasis correlation with prognosis in patients with T2 gastric cancer. PLoS ONE. 2014;9(8):e105112.CrossRefGoogle Scholar
  28. 28.
    Nitti D, Marchet A, Mocellin S, Rossi GM, Ambrosi A, Mencarelli R. Prognostic value of subclassification of T2 tumours in patients with gastric cancer. Br J Surg. 2009;96(4):398–404.CrossRefGoogle Scholar
  29. 29.
    Oh SY, Lee KG, Suh YS, et al. Lymph node metastasis in mucosal gastric cancer: reappraisal of expanded indication of endoscopic submucosal dissection. Ann Surg. 2016;265:1.Google Scholar
  30. 30.
    Pokala SK, Zhang C, Chen Z, et al. Lymph node metastasis in early gastric adenocarcinoma in the United States of America. Endoscopy. 2018;50(5):479–486.CrossRefGoogle Scholar
  31. 31.
    Gotoda T, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, Kato Y. Incidence of lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3(4):219–225.CrossRefGoogle Scholar
  32. 32.
    Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;8:394–424.CrossRefGoogle Scholar
  33. 33.
    Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132.CrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2019

Authors and Affiliations

  • Qi-Yue Chen
    • 1
    • 2
    • 3
    • 4
  • Qing Zhong
    • 1
    • 2
    • 3
    • 4
  • Zhi-Yu Liu
    • 1
    • 2
    • 3
    • 4
  • Jian-Wei Xie
    • 1
    • 2
    • 3
    • 4
  • Jia-Bin Wang
    • 1
    • 2
    • 3
    • 4
  • Jian-Xian Lin
    • 1
    • 2
    • 3
    • 4
  • Jun Lu
    • 1
    • 2
    • 3
    • 4
  • Long-Long Cao
    • 1
    • 2
    • 3
    • 4
  • Mi Lin
    • 1
    • 2
    • 3
    • 4
  • Ru-Hong Tu
    • 1
    • 2
    • 3
    • 4
  • Ze-Ning Huang
    • 1
    • 2
    • 3
    • 4
  • Ju-Li Lin
    • 1
    • 2
    • 3
    • 4
  • Ping Li
    • 1
    • 2
    • 3
    • 4
    Email author
  • Chao-Hui Zheng
    • 1
    • 2
    • 3
    • 4
    Email author
  • Chang-Ming Huang
    • 1
    • 2
    • 3
    • 4
    Email author
  1. 1.Department of Gastric SurgeryFujian Medical University Union HospitalFuzhouChina
  2. 2.Department of General SurgeryFujian Medical University Union HospitalFuzhouChina
  3. 3.Key Laboratory of Ministry of Education of Gastrointestinal CancerFujian Medical UniversityFuzhouChina
  4. 4.Fujian Key Laboratory of Tumor MicrobiologyFujian Medical UniversityFuzhouChina

Personalised recommendations